Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call presented mixed signals. While there are positive developments like improved DT-216P2 formulation and a strong cash position, there are concerns about competition, regulatory uncertainties, and measurement challenges. The Q&A highlighted unresolved issues, particularly around accelerated approval and measurement methods. Despite some optimism in product development, the risks and uncertainties balance out the positives, leading to a neutral sentiment.

Key Q&A

Q:- Joseph Schwartz (Leerink Partners): Could you explain the tissue distribution relative to plasma distribution for DT-216P2 and the ISR profile for the original and new formulations?

A: - The exposure profile for DT-216P2 indicates that the levels of drug required in tissue are similar to the in vitro EC90, setting a target. The new drug product, DT-216P2, shows no disconnect between plasma and tissue levels in animals, aligning with small molecule drug expectations.

Q:- Unidentified Analyst (RBC Capital Markets): How are you planning to design Phase 1 for DT-216P3, potential accelerated approval, and patient numbers for the study?

A: - Phase 1 will start with a PK study in healthy volunteers to confirm the PK profile of DT-216P2 before patient studies in 2025. Regarding accelerated approval, the high unmet need may potentially open a path forward, but specifics on FDA requirements remain to be determined upon clinical study resumption.

Q:- Laura Chico (Wedbush): What developments have been made in measuring frataxin levels and any insights into Fuchs disease progression and measurement challenges?

A: - Efforts are ongoing to improve measurement of frataxin protein levels. Regarding Fuchs disease, an observational study in patients with a confirmed TCF4 mutation will assess visual quality measures, edema in the cornea, and ways to visualize the corneal endothelium for disease progression evaluation.

You have reached the limit Upgrade to access full content

Get started

DSGN Transcript

Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript

Neutral9-5

Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

Unknown3-20

DSGN Report

Design Therapeutics, Inc. 10-Q

10-Q

2024-08-05

Design Therapeutics, Inc. 10-Q

10-Q

2024-05-08

Design Therapeutics, Inc. 10-K

10-K

2024-03-19

Design Therapeutics, Inc. 10-Q

10-Q

2023-11-13

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.